Logo

BMS' Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive EC's Approval for 1L Treatment of Advanced Renal Cell Carcinoma

Share this

BMS' Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive EC's Approval for 1L Treatment of Advanced Renal Cell Carcinoma

Shots:

  • The approval is based on P-III CheckMate -9ER trial involves assessing Opdivo + Cabometyx vs sunitinib in 651 patients with previously untreated advanced or metastatic RCC
  • Results: @median follow-up of 10.6 mos.; m-PFS (16.6 vs 8.3mos.)- ORR (55.7% vs 27.1%); CR (9.3% vs 4.3%); OS (40% reduction in risk of death)- Grade 3+ AEs (75% vs 71%)- was well tolerated with a low rate of TREA leading to discontinuations (5.6 % vs 8.8%)
  • Two Opdivo-based therapies (Opdivo + Yervoy & Opdivo + Cabometyx) are now authorized for 1L treatment of patients with advanced RCC in EU countries

  Ref: Business Wire | Image: BMS

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions